Vivoryon Therapeutics N.V.
VVY.AS · AMS
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | -€4 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €1 |
| Gross Profit | -€0 | -€0 | -€0 | -€4 |
| % Margin | – | – | – | 114.5% |
| R&D Expenses | €3 | €4 | €10 | €11 |
| G&A Expenses | €3 | €3 | €4 | €4 |
| SG&A Expenses | €3 | €3 | €4 | €4 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | €0 | -€0 | -€0 |
| Operating Expenses | €6 | €7 | €14 | €15 |
| Operating Income | -€6 | -€7 | -€14 | -€18 |
| % Margin | – | – | – | 501.2% |
| Other Income/Exp. Net | €0 | €0 | €0 | €0 |
| Pre-Tax Income | -€5 | -€7 | -€14 | -€18 |
| Tax Expense | €0 | €0 | €0 | -€0 |
| Net Income | -€5 | -€7 | -€14 | -€18 |
| % Margin | – | – | – | 486.9% |
| EPS | -0.21 | -0.27 | -0.52 | -0.72 |
| % Growth | 22.2% | 48.1% | 27.8% | – |
| EPS Diluted | -0.21 | -0.27 | -0.52 | -0.72 |
| Weighted Avg Shares Out | 26 | 26 | 26 | 25 |
| Weighted Avg Shares Out Dil | 26 | 26 | 26 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€5 | -€7 | -€14 | -€18 |
| % Margin | – | – | – | 483.5% |